The compound library

With more than 10 years of accumulation, KBP has built a small molecule compound library with over 3,000,000 number of chemical compounds, range from compounds which designed and synthesized by KBP with unique structure and high potency, to natural product library of compounds extracted from plants, marine organisms and microorganisms,  as well as a diverse compound library with synthesized based on different core structures that cover almost all of core structures.

Coupled with bio-evaluation technology platform, the compound library supported KBP to identify and progress unique drugs that fit global unmet medical need quickly and efficiently.

Over 100 lead compounds have been screened from the library, and 3 compounds have entered into international clinical development.


The Bacteria Collection

KBP’s bacteria collection has more than 30,000 isolates, including Gram-positive and Gram-negative aerobic bacteria, anaerobic bacteria and clinical special pathogenic strains, covering 33 species and more than 200 classes of strains.   KBP has established cooperative relations with more than 20 top hospitals (mostly in China), and will continue to find new partners for collecting difficult isolation strains, such as Anaerobic bacteria and Helicobacter pylori.

With the continuous improvement of the type and number of strains, KBP’s bacteria collection will provide strong support to the development of new antibiotics that fit the global unmet medical need.


Pharmacological experiment platform

KBP’s own pharmacology experimental platform is the basis for compound screening, optimization, preclinical pharmacology, toxicology, and pharmacological mechanisms study. The pharmacological experiment platform was established around the three major therapeutic areas (organ protection, inflammation and autoimmune, anti-infection).  The platform include pharmacology models, toxicology model and pharmacokinetic model, across different animal models.

The platform is well integrated with KBP’s compound library and the bacteria collection.  The pharmacology experimental platform allow KBP to identify and progress those products with significant differentiation and clinical, market advantage.